Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994951 | 1.00 | KMT2A (0.41) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2996479 | 0.90 | DYRK3 (0.42) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2996481 | 0.90 | DYRK3 (0.42) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2992895 | 0.88 | NPC1 (0.39) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2990900 | 0.88 | ALOX5 (0.44) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2990895 | 0.88 | ALOX5 (0.44) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2992893 | 0.88 | NPC1 (0.39) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2989589 | 0.87 | NPC1 (0.41) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL2989591 | 0.87 | NPC1 (0.41) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL4949454 | 0.87 | CISD1 (0.40) | KMT2ANPC1RAB9AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | claimed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | claimed |
| EP-1993538-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2007103758-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | claimed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | claimed |
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | disclosed |
| EP-2164494-A1 | METHODS OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| WO-2008150837-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-1993538-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007103758-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | KMT2A 3096/4885NPC1 2430/4885RAB9A 1514/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | KMT2A 2272/4885NPC1 2692/4885RAB9A 2892/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | KMT2A 3294/4885NPC1 2040/4885RAB9A 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.